People with cancer may encounter checkpoint inhibitors as a treatment option but may not know where to start. This article ...

Novo Nordisk has dosed the first subject in a Phase I clinical trial of the oral NLRP3 inhibitor NNC6022-0001 (formerly known ...

In preclinical studies, VYN202 achieved consistent reductions in pro-inflammatory and disease-related biomarkers and improvements in disease severity across a variety of inflammatory and fibrotic ...

Remarkably, UH15-38 significantly improved survival outcomes even when given 5 days after infection. This contrasts with the ...

With $6.5 million in seed funding, Pepper Bio has decided to shake up its portfolio by acquiring a CDK4/6 inhibitor from G1 ...

Recent regulatory warnings could mean that four in five patients with RA may not be prescribed JAK inhibitors unless there is no other alternative.

Ventus Therapeutics’ partner Novo Nordisk doses first participant in phase 1 study of NNC6022-0001, an oral NLRP3 inhibitor: Waltham, Massachusetts Monday, May 6, 2024, 15:00 Hr ...

FDA approved Mirum Pharmaceuticals' Limvarli for treatment of cholestatic pruritus in patients with PFIC. Learn why I rate ...

Sanofi’s rilzabrutinib met the primary endpoint in the Phase III persistent or chronic immune thrombocytopenia trial.

Leerink Partners analyst Andrew Berens has maintained their bullish stance on BOLD stock, giving a Buy rating on April 22. Andrew Berens has ...

The U.S. Food and Drug Administration has approved Genentech's Alecensa (alectinib) as adjuvant treatment following tumor ...

A new study shows that an inhibitor called ESI1 could potentially treat multiple sclerosis and other conditions associated with demyelination.